

isolating said polypeptide from said host cell.

A<sup>3</sup> 24. (Amended) A polypeptide obtainable by the method of claim 21.

28. (Amended) The method of claim 25 or claim 26 wherein the SGK is SGK activated by phosphorylation.

A<sup>4</sup> 29. (Amended) The method of claim 25 or claim 26 wherein the activity of the SGK is decreased in the presence of the compound.

30. (Amended) The method according to claim 25 or claim 26 wherein the activity of the SGK is increased in the presence of the compound.

A<sup>5</sup> 34. (Amended) A kit of parts useful in carrying out a method according to any one of claims 25, 26, 31, 32 or 33.

A<sup>6</sup> 37. (Amended) A compound identifiable or identified by a method according to any one of claims 25, 26, 31, 32 or 33.

42. (Amended) The use according to claim 39 wherein the patient has cancer.

A<sup>7</sup> 43. (Amended) The use according to claim 39 wherein the patient has diabetes or ischaemic disease.

44. (Amended) The method according to any one of claims 1, 2, 7, 8, 25, 26 or 31-33 wherein the said SGK is SGK1, SGK2 $\alpha$ , SGK2 $\beta$  or SGK3.

Add new claims 45-50 as follows (also provided on the marked-up copy of the claims):

A<sup>8</sup> --45. (New) A host cell comprising a polynucleotide as defined in claim 19.--

--46. (New) The method according to claim 40 wherein the patient has cancer.--

--47. (New) The method according to claim 40 wherein the patient has diabetes or ischaemic disease.--

--48. (New) The use according to any one of claims 5, 6 or 41 wherein the said SGK is SGK1, SGK2 $\alpha$ , SGK2 $\beta$  or SGK3.--

--49. (New) The fusion polypeptide according to claim 11 wherein the said SGK is SGK1, SGK2 $\alpha$ , SGK2 $\beta$  or SGK3.--